Ionis Pharmaceuticals (IONS) Gross Profit (2018 - 2026)

Ionis Pharmaceuticals' Gross Profit history runs 9 years deep, the most recent figure standing at $265.2 million for Q2 2026.

• In Q2 2026, Gross Profit fell 40.79% year-over-year to $265.2 million; the TTM figure through Jun 2026 stood at $662.0 million (down 29.09% YoY), while the FY2025 annual figure was $927.8 million, up 33.7% from the prior year.
• Gross Profit for Q2 2026 stood at $265.2 million, up from $47.0 million in the prior quarter.
• The five-year high for Gross Profit was $447.9 million in Q2 2025, with the low at $47.0 million in Q1 2026.
• The 5-year median for Gross Profit is $151.3 million (2022), against an average of $182.5 million.
• The sharpest annual moves came in 2022 and 2023: Gross Profit slumped 66.15% in 2022, then soared 116.89% in 2023.
• Ionis Pharmaceuticals' Gross Profit stood at $148.2 million in 2022, then surged by 116.89% to $321.4 million in 2023, then plunged by 30.7% to $222.7 million in 2024, then dropped by 12.29% to $195.4 million in 2025, then soared by 35.75% to $265.2 million in 2026.
• Business Quant data shows IONS's Gross Profit at $265.2 million in Q2 2026, $47.0 million in Q1 2026, and $195.4 million in Q4 2025.